A new publication referencing teriparatide was announced on November 12, 2026. The study, titled "Real-world treatment patterns following denosumab discontinuation: a descriptive epidemiological study," appeared in the journal Archives of Osteoporosis.
The publication is described as a descriptive epidemiological study. It focuses on treatment patterns observed after patients discontinued denosumab therapy. No specific findings, outcomes, or results from the study have been provided at this time.
Teriparatide remains an approved compound. This entry reflects only the existence and title of the newly listed publication, not any conclusions drawn within it.
Readers interested in background on teriparatide can consult the compound overview for additional context.